GLP-1 medications like semaglutide and tirzepatide mimic naturally occurring gut hormones that regulate appetite, slow gastric emptying, and improve blood sugar control
Optimal dosing is still being refined
Although there has been no direct head-to-head study comparing between the two preparations of semaglutide, the SUSTAIN-1 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide against placebo in 387 T2D patients using a similar study design and patient population to PIONEER-1
That third receptor, glucagon, is the game changer
Patients can present with the following signs & symptoms: CNS (areflexia, asthenia, ataxia, blurred vision, disorientation, dizziness, drowsiness, hyporeflexia, slurred speedh, somnolence, staggering, tiredness, coma) Cardiovascular (initial hypertension, followed by long-lasting hypotension , bradycardia , premature ventricular beats) the peripheral actions of xylazine cause an initial increase in blood pressure, followed by central effects that result in a long-lasting hypotensive effect, accompanied by bradycardia and reduced cardiac output (Hoffman et al, 2001)